Drug intelligence / Profile preview

3G5 (Otsuka anti-IL1RAP)

Development stage: Unknown
Lead developer: Otsuka Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

3G5 (Otsuka anti-IL1RAP): sourced facts only. name: "In addition to the lead candidate, the program includes a pre-clinical back-up IL1RAP antibody, 3G5." [1] target: "In addition to the lead candidate, the program includes a pre-clinical back-up IL1RAP antibody, 3G5." [2] developer: "closed Otsuka's acquisition of the anti-IL1RAP antibody program CAN10 from Cantargia." [1] stage: "In addition to the lead candidate, the program includes a pre-clinical back-up IL1RAP antibody, 3G5." [1] modality: "In addition to the lead candidate, the program includes a pre-clinical back-up IL1RAP antibody, 3G5." [1]

Targets

IL1RAP (Interleukin 1 receptor accessory protein)

Beyond the preview

Go deeper on 3G5 (Otsuka anti-IL1RAP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3G5 (Otsuka anti-IL1RAP).